Page 30 - Revol11
P. 30
Liberman R y Kopellwicz A. Un enfoque empírico de la recuperación de la esquizofrenia: definir la recuperación e identificar los factores
que pueden facilitarla
17. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The 38. Bowers MB, Mazure CM, Nelson JC, Jatlow PI. Psychotogenic
Vermont longitudinal study of persons with severe mental illness: drug use and neuroleptic response. Psychiatr Bull 1990; 16:81-5.
II. Long-term outcome of subjects who retrospectively met DSM-
III criteria fro schizophrenia: Am J Psychiatry 1987;144: 727-35. 39. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with
psychosis: demographic characteristics, clinical features, and fa-
18. Huber G, Gross G, Schuttler R. A long-term follow-up study of mily history. Arch Gen Psychiatry 1982; 39:141-7.
schizophrenia: psychiatric course of illness and prognosis. Acta
Psychiatri Scand 1957; 52:49-57. 40. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB.
Substance use: A powerful predictor of relapse in schizophrenia.
19. Ogawa K, Miya M, Watarai A, Nakazawa M, Yuasa S. Utensa H. Schizophr Res 1996; 20:145-51.
A long-term follow-up study of schizophrenia in Japan with spe-
cial reference to the course of social adjustment. Br J Psychiatry 41. Lyons JS, McGovern MP. Use of mental health services by dually
1987; 151:758-65. diagnosed patients. Hosp Community Psychiatry 1989; 40:1067-9.
20. Harding CM, Zubin J, Strauss JS. Chronicity in schizophrenia: 42. Swanson JW, Holzer CE, Ganju VK, Jono RT. Violence and psy-
Revisited. Br J Psychiatry 1992; 161 (Suppl 18):27-37. chiatric disorder in the community: Evidence from the Epide-
miologic Catchment Area surveys. Hosp & Community
21. Palmer BW, Heaton SC, Jeste DV. Older patients with schizoph- Psychiatry 1990; 41:761-70.
renia: Challenges in the coming decades. Psychiat Serv 1999;
50:1178-83. 43. Cuffel BJ. Violent and destructive behavior among the severely
mentally ill in rural areas: Evidence from Arkansas’ community
22. Paul GL, Lentz RJ. Psychosocial treatment of chronic mental pa- mental health system. Community Ment Health 1994; 30:495-
tients: milieu versus social-learning programs. Cambridge, Mass.: 504.
Harvard University Press, 1977.
44. Warner R, Taylor D, Wright J, Sloat A, Springett G, Arnold S, et
23. DeSisto MJ, Harding CM, McCormick RV, Ashikaga T, Brooks al. Substance use among the mentally ill: Prevalence, reasons for
GW. The Maine and Vermont three-decade studies of serious use and effects on illness. A J Orthopsychiatry 1994; 64:30-9.
mental illness. I. Matched comparison of cross-sectional outco-
me. Br J Psychiatry 1995;167:331-8. 45. Shaner A, Roberts LJ, Eckman TA, Racenstein JM, Tucker DE,
Tsuang JW, et al. Sources of diagnostic uncertainty for chronically
24. DeSisto MJ, Harding CM, McCormick RV, Ashikaga T, Brooks psychotic cocaine abusers. Psychiatr Serv 1998; 49:684-90.
GW. The Maine and Vermont three-decade studies of serious
mental illness. II. Longitudinal course comparisons. Br J Psy- 46. Lo WH, Lo T. A ten-year follow-up study of Chinese schizophre-
chiatry1995;167:338-42. nic in Hong Kong. Br J Psychiatry 1977; 131:63-6.
25. Strauss JS, Carpenter WT. The prediction of outcome in schi- 47. Crow TJ, MacMillan JF, Johnson AL, Johnstone E. The North-
zophrenia: II. Relationships between predictor and outcome va- wick Park study of first episodes of schizophrenia: II. A randomi-
riables: a report from the WHO International Pilot Study of zed controlled trial of prophylactic neuroleptic treatment. Br J
Schizophrenia. Arch Gen Psychiatry 1974; 31:37-42. Psychiatry 1986;148:120-7.
26. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, 48. Fenton WS, McGlashan TH. Sustained remission in drug-free
et al. Conceptualization and rationale for consensus definitions schizophrenic patients. Am J Psychiatry 1987;144:1306-9.
of terms in major depressive disorder: Remission, recovery, re-
lapse, and recurrence. Arch Gen Psychiatry 1991; 48:851-5. 49. Helgason L. Twenty years’ follow-up of first psychiatric presenta-
tion for schizophrenia: What could have been prevented? Acta
27. World Health Organization. International Classification of Im- Psychiatr Scand 1990; 81:231-5.
pairment, Disabilities, and Handicaps. Geneva: World Health Or-
ganization, 1980. 50. Wyatt RJ. Neuroleptics and the natural course of schizophrenia.
Schizophr Bull 1991; 17:325-51.
28. Sturm R, Gresenz C, Pacula R, Wells K. Labor force participation
by persons with mental illness. Psychiatr Serv 2000; 50:1407. 51. Lieberman JA, Fenton WS. Delayed detection of psychosis: cau-
ses, consequences and effect on public health. Am J Psychiatry
29. Ventura J, Green MF, Shaner A, Liberman RP. Training and qua- 2000; 157:1727-30.
lity assurance ion the use of the Expanded Brief Psychiatric Ra-
ting Scale: the “drift busters”. Intern J Methods in Psychiatr Res 52. McGlashan TK. Early detection and intervention in schizophre-
1993; 3:221-44. nia: Research. Schizophr Bull 1996; 22:327-45.
30. Frese FJ, Stanley J, Kress K, Vogel-Scibilia S. Integrating eviden- 53. McGlashan TK. Symposium on intervention for the psychotic
ce-based practices and the recovery model. Psychiatr Serv 2001; prodrome, presented at the Annual Meeting of the American Psy-
52:1462-8. chiatric Association, May 2001.
31. Liberman RP, Wallace CJ, Blackwell G, Eckman TA, Vaccaro JV, 54. May PR, Van Putten T, Yale C. Predicting outcome of antipsy-
Kuehnel TG. Innovations in skills training for the seriously men- chotic drug treatment from early response. Am J Psychiatry 1980;
tally ill: The UCLA Social & Independent Living Skills modules. 137:1088-9.
Innovations and Research 1993; 2:43-60.
55. Awad AG, Hogan TP. Early treatment events and prediction of
32. Bebbington P, Kuipers L. The predictive utility of expressed emo- response to neuroleptics in schizophrenia. Prog in Neuropsy-
tion in schizophrenia: An aggregate analysis. Psychol Med 1994; chopharmacol Biol Psychiatry 1985; 9:585-8.
24:707-18.
56. Klimke A, Kleiser E, Lehman E, Miele L. Initial improvement as a
33. Butzlaff RL, Hooley JM. Expressed emotion and psychiatric re- criterion for drug choice in acute schizophrenia. Pharmacopsy-
lapse. Arch Gen Psychiatry 1998; 55:547-52. chiatry 1993; 26: 25-9.
34. Barrowcljough C, Tarrier N. Social functioning and family interven- 57. Ayers T, Liberman RP, Wallace CJ. Subjective response to an-
tions. En: Mueser KT, Tarrier N, editors. Handbook of social func- tipsychotic drugs: failure to replicate predictions of outcome.
tioning in schizophrenia. Boston, MA: Allyn & Bacon, 1998; p. J-Clin Psychopharmacol 1984; 4:89-93.
327-41.
58. Davis JM. Overview: maintenance therapy in psychiatry: I. Schi-
35. Falloon IRH, Held T, Cloverdale JH, Roncone R, Laidlaw TM. zophrenia. Am J Psychiatry 1975; 132:1237-45.
Family interventions for schizophrenia: A review of international
studies of long-term benefits. Psychiatric Rehabilitation Skills 59. Hoge Sk, Appelbaum PS, Lawlor T, Beck JC, Litman R, Greer
1999; 3:268-90. A, et al. A prospective, multicenter study of patients’ refusal
of antipsychotic medication. Arch Gen Psychiatry 1990;
36. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et 47:949-56.
al. Comorbidity of mental disorders with alcohol and other drug
abuse: Results from the Epidemiologic Catchment Area (ECA) 60. Weiden P, Olfson M, Essock S. Medication noncompliance in
study. JAMA1990; 264:2511-8. schizophrenia: Effects on mental health service policy. En:
Blackwell B, editor. Treatment compliance and the therapeutic
37. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown alliance. Nueva York: Harwood Academic Publishers, 1997; p.
GM, Franco S. Substance abuse and schizophrenia: Effect on 35-60.
symptoms but not on neurocognitive function. J Clin Psychiatry
1991; 52:26-30. 61. Corrigan PW, Liberman RP, Engel J. From compliance to adhe-
rence in psychiatric treatment: Strategies that facilitate collabora-
tion between practitioners and patient. Hosp Community
Psychiatry 1990; 41:1203-11.
Rehabilitación psicosocial 2004; 1(1):12-29 27
